In the realm of speculative science, the line between science fiction and commercial reality is thinning. Colossal Biosciences, the five-year-old startup that captured global headlines with its ambitious—and controversial—plan to “resurrect” the woolly mammoth, is once again defying skeptics. According to reports, the Dallas-based venture is currently in advanced discussions for a new funding round that would catapult its valuation to between $20 billion and $30 billion.
This meteoric rise, up from a $10.2 billion valuation just 16 months ago, underscores a broader shift in the venture capital landscape. Investors are increasingly moving away from software-as-a-service (SaaS) and toward “hard tech” or “deep tech”—sectors where proprietary scientific advancements in biology, longevity, and synthetic environments promise to reshape the foundational pillars of human existence.
The Evolution of a De-Extinction Startup
When Colossal first announced its mission to bring back the dire wolf using genetic material extracted from ancient fossils, the project was met with a chorus of academic skepticism and ethical hand-wringing. Critics questioned the viability of reintroducing extinct apex predators into modern ecosystems. However, behind the flashy headlines of “mammoth revival,” CEO and co-founder Ben Lamm was quietly building a robust intellectual property portfolio.
The pivot from a singular focus on de-extinction to a diversified biotech conglomerate has been the engine behind the company’s current valuation. By framing its core scientific research—gene editing, synthetic biology, and computational modeling—as dual-use technologies, Colossal has managed to secure both government contracts and venture capital interest.
A Chronology of Rapid Expansion
To understand how a startup focused on extinct species commands a valuation rivaling established tech giants, one must look at the company’s aggressive developmental timeline:
- Foundation (2021): Colossal Biosciences is established in Dallas, Texas, with a mission to utilize CRISPR technology to restore extinct species to their former habitats.
- The Mammoth Milestone (2025): Following a $200 million raise, the company cements its $10.2 billion valuation, positioning itself as a leader in the de-extinction space.
- The Spinoff Strategy (2025–2026): Recognizing the commercial potential of its internal tools, Colossal begins spinning off specialized entities. Breaking (plastics degradation) and Form Bio (computational biology) are launched to capture markets outside of pure conservation.
- AI Integration (March 2026): Astromech, the company’s AI-driven predictive modeling arm, achieves a staggering $2 billion valuation, proving that the firm’s algorithmic approach to biology has massive enterprise value.
- Portfolio Diversification (April–May 2026): The company expands its target list to include the bluebuck antelope and announces the imminent release of artificial womb technology.
- Current State (July 2026): Negotiations for a funding round aiming at a $20 billion to $30 billion valuation are reported, signaling strong institutional appetite for high-risk, high-reward biotech.
Supporting Data: The Revenue Streams
The central critique of Colossal has always been: "How does a company that brings back the dodo bird make money?" Ben Lamm’s strategy relies on a sophisticated tripartite revenue model that decouples the scientific research from the eventual rewilding projects.
1. Conservation-as-a-Service
Colossal has successfully marketed its proprietary gene-editing and conservation tools to state actors. The U.S. government has expressed interest in these methodologies, and the UAE has already committed $60 million to the firm. This represents a pivot from private-sector research to public-private partnerships, where the state funds the development of biodiversity preservation technologies.
2. Commercial Spinoffs
The company’s ability to monetize its R&D through spinoffs is perhaps its most impressive feat. By creating distinct entities for specific verticals, Colossal allows investors to bet on the technology without necessarily betting on the “mammoth” project.
- Breaking: Tackles the global crisis of plastic waste, a massive market with clear B2B potential.
- Form Bio: Provides a computational platform for the broader biotech industry, generating recurring revenue through software licensing.
- Astromech: Utilizes AI for biological predictive modeling, a high-growth sector that sits at the intersection of Big Tech and Pharma.
3. Future Biodiversity Credits
Perhaps the most speculative, yet potentially lucrative, revenue stream is the proposed “biodiversity credit” market. Similar to the carbon credit market—which has grown into a multi-billion dollar industry—Lamm envisions a future where the reintroduction of extinct species provides ecological services that can be monetized. While the regulatory framework for such credits is still in its infancy, Colossal is positioning itself as the primary infrastructure provider for this future market.
The Human Element: Artificial Wombs and Beyond
Perhaps the most controversial and significant development is the company’s work on "artificial animal womb" technology. While the primary goal is to facilitate the gestation of extinct species, the technology possesses immediate applications for human reproductive medicine.
In May 2026, reports suggested that the company’s artificial womb technology is nearing a state of functional readiness, with a projected debut in the coming year. If successful, this technology could revolutionize fertility treatments, potentially offering a solution for those who cannot conceive naturally. The move from animal biology to human-adjacent medical tech represents a significant shift in Colossal’s risk profile—and its potential reward.
Official Responses and Industry Context
Despite the buzz, Colossal remains tight-lipped regarding the specifics of the current fundraising round. A request for comment sent to the company’s Dallas headquarters went unanswered, which is consistent with the firm’s historical approach to sensitive financial negotiations.
The silence, however, is being filled by market analysts who point to the broader “Deep Tech” boom. With alternative energy, longevity tech, and AI-driven healthcare receiving massive inflows of capital, Colossal is benefiting from a “rising tide” effect. Investors are no longer content with incremental software improvements; they are hunting for companies that promise to solve existential problems—whether those problems are climate change, species extinction, or human infertility.
Implications: The Ethics of a $30 Billion Valuation
The valuation of Colossal at $30 billion would be a watershed moment for biotechnology. It signals that the market is willing to assign massive value to “moonshot” projects that have long gestation periods and high technical risk.
However, the implications go beyond finance. If a company can achieve such scale by commodifying the building blocks of life, it raises profound questions about ownership, regulation, and the ethics of synthetic biology. Who owns the genetic rights to a resurrected species? What are the ecological ramifications of releasing lab-grown organisms into the wild? And, perhaps most importantly, to what extent should the profit motive drive the creation of life?
As Colossal Biosciences continues its march toward these ambitious goals, it remains a litmus test for the future of the biotech industry. Whether it succeeds in its mission to bring back the woolly mammoth or simply succeeds in building a suite of high-value tools for the modern age, one thing is certain: the company has fundamentally changed the conversation around what is possible in the laboratory.
In the coming months, as the details of this new funding round emerge, the industry will be watching closely. If the capital is secured, Colossal will move from the realm of "promising startup" to a dominant player in the global scientific infrastructure, capable of influencing both the natural world and the future of human biology for decades to come.
Nana Muazin
Neng Nana
Lina Hope
